Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies

The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia. Mounting preclinical and clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Sining, Jung, Jaeyong, Victor, Eton, Arceo, Johann, Gokhale, Samantha, Xie, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585514/
https://www.ncbi.nlm.nih.gov/pubmed/34778053
http://dx.doi.org/10.3389/fonc.2021.737943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585514/
https://www.ncbi.nlm.nih.gov/pubmed/34778053
http://dx.doi.org/10.3389/fonc.2021.737943

Ejemplares similares